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THE extensive and detailed studies made on various resistant experimental
tumours offer considerable help in the recognition ofthe mechanism ofanti-cancer
activity.
Similarly to the antimetabolite-resistant tumours a number of strains have
been developed showing varying degrees of resistance to the biological alkylating
agents. Hirono (1954) made one of the first investigations of the resistance with
N-mustard-N-oxide. Since then many resistant sublines have been developed
and reported in the last years.
Ujhazy and Winkler (1965) have prepared and studied a Yoshida sarcoma line
resistant to nitrogen mustard and Gati and Kellner strains which are resistant
to Degranol (Gati, 1965). Myura (1961) and Moriwaki (1963) have described
mustard-resistant ascites hepatoma strains and have demonstrated the acquired
resistance of these sub-strains to alkylating cytostatics. Most frequently the
resistant strains are developed by adaptation. Animals are treated with non-
curative doses of a cytotoxic agent throughout a large number of passages of the
originally sensitive tumour, when an increasing degree ofresistance ofthe tumour
to the chemotherapeutic agent develops. This seems to be afairlyreliable method
and resistance developed in this way is usually hereditary.
Sakurai (1963) suggested an in. vitro method for the study of resistance.
According to his data, neoplastic cells incubated with N-mustard displayed
resistance of several hundredfold towards this agent after only one or two periods
of incubation with the drug.
The degree of resistance is usually determined by in vivo experiments, though
Moriwaki (1963) suggested the use of an in vitro method.
The anti-neoplastic and haematologic effects of 1,6-dibromo-1,6-dideoxy-D-
mannitol (DBM), Myelobromol were first described in 1961 (Csanyi et al. 1961,
1964, 1965). Although the chemical structure of this compound differs from that
of other known biological alkylating agents, earlier experiments have not shown
that it has a different mechanism of action (Institoris et al., 1964b, Horvath et al.,
1966). The compound has been applied clinically underthe name ofMyelobromol,
mainly for the treatment of chronic myeloid leukaemia (Sellei, 1963, Sellei and
Eckhardt, 1963; Eckhardt et al., 1963, 1964). Good results have been obtained
even in cases resistant to other cytostatic agents (Myeleran, Mannitol-Myleran,
X-ray therapy etc.).
To gain a more thorough insight into the mechanism of action of DBM, a
DBM-resistant Yoshida-sarcoma line has been developed and a number of cross-
resistance tests have been carried out to demonstrate the existence of, or lack of,
cross-resistance to biological alkylating agents of various types to antibiotics, to
antimetabolites and to mitotic poisons.
The new tumour line developed from Yoshida-sarcoma has been named
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METHODS
The first experiment has been done in order to produce DBM-resistant Yoshida
sarcoma strains by Sakurai's itf vitro method (1963). The recommended concen-
tration of 5 x 10-4 31/ml. was, however, too high in the case of DBM, as this dose
resulted in the complete inhibition of " takes ". Repeated use of single lower
doses, oIn the other hand, produced no resistance whatsoever. Contrary to
Sakurai's experiences with nitrogen mustard, where resistance developed after
only 1 or 2 incubation periods, a certain degree of resistance was observed onlv
after 15 incubation passages.
The preparation of a more highly resistant tumour strain was as follows:
From the fifth day after subcutaneous implantation of the Yoshida sarcoma
the rats were treated on three successive days with 30 mg. per kg. of DBM i.p.
The tumours were transplanted one week after the end of the treatment. In the
following periods up to the eighth generation the beginning ofthe DBM treatment
was gradually brought closer to the time of implantation, also, the dose was
raised gradually to 70 mg. per kg. Development of resistance was first demon-
strated clearly with the eighth treated generation of the tumour. From the
eighth to the fifteenth generation the rats were treated with 6 x 70 mg. per kg.
of DBM i.p. and the tumours were transplanted every eighth day. The degree
of resistance was determined from the 20th and 40th generation; cross-resistance
tests were carried out from the 20th to 25th generation.
The animals used in the experiments were female CB WVistar rats with a body
weight of 150-200 g. For tumour implantation the usual subcutaneous trocar
technique was used. The water soluble agents were dissolved in physiological
saline, the insoluble compounds suspended in Tween-80 and all were administered
intraperitoneally. The experiments were evaluated by using the weight of the
tumours on the eighth or ninth day.
RESULTS
Presence and degree of resistance
From the eighth treated generation the difference between the inhibitory
effect of 100 mg./kg. DBM obtained on sensitive and resistant tumours growing
in the same animals was already significant. The degree of resistance was first
determined after the 20th generation. The results are summarized in Table I.
The effect of DBM on sensitive and resistant 20th generation Yoshida s.c. sarcoma
According to the data in the Table I showing the high degree of acquired
resistance, a significant inhibition was obtained only with subtoxic doses of DBM
on D-Yoshida sarcoma. For the cross-resistance tests the doses of the agents
were chosen in such a way as to produce the maximum possible effect on sensitive
Yoshida sarcoma.
The agents used for the test belong to the following classes:
1. Biological alkylating agents:
(a) nitrogen mustards
(b) ethyleneimines
(c) methanesulphonates
(d) halogenated sugar alcohols
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2. Antimetabolites (a) folic acid antagonists
(b) purine, pyrimidine antagonists
3. Mitotic poisons
4. Antibiotics.
TABLE I.
Yoshida s.c. sarcoma D-Yoshida s.c. sarcoma
Dose Weight of Weight of Change in
mg/kg tumour Inhibition tumour Inhibition body-weight
5 x i.p. mg. % mg. % %
Control . 2110 - . +
2 . 1400 34 . +
5 550 72 . +
15 . 198 90 . . +
45 20 99.9 . +
Control . . 1960 . 0
200 . 2250 0 0
400 . 1630 23 . -6
800 . . 873 58 6 . -18
Each group contained eight animals
ED50 D-Yoshida s.c. sarcoma = 3500 mg. per kg.
= 260
ED50 Yoshida s.c. sarcoma = 13-5 mg. per kg.
Thus the degree of resistance is 260.
Cross-resistance tests on Yoshide s.c. sarcoma and on DBM11-resistant D-Yoshida s.c.
sarcoma
The degree ofinhibition obtained with the two types oftumours were compared
in both cases with their own controls. The level of significance was calculated
by comparing the numerical value ofinhibition obtained with D-Yoshida sarcoma
to the inhibition obtained on the sensitive tumour.
The data ofTable II provides evidence ofthe resistance ofD-Yoshida sarcoma
to a variety ofbiological alkylating agents and also to Mitomycin C. The tumour
however, retained its sensitivity to antimetabolites and mitotic poisons.
DISCUSSION
1,6-Dibromo-1,6-dideoxy-D-mannitol/DBM/represents anewtypeofcompound
in the family of biological alkylating agents, as its molecule contains none of the
known biological alkylating moieties, such as dichloroethylamine, ethyleneimine,
mesyl or epoxide groups.
We described in our earlier papers (Institoris et al., 1961; Institoris and
Horvaith 1964) that as far as its action is concerned DBM seems to be similar to
1,6-dimesyl-mannitol. Its haematological effect is directed mainly to the myeloid
system.
In our studies of the action-structure relationships we have shown (Institoris
et al., 1964) that for the action ofDBM not only the pair ofBr atoms are important
but the whole of the dibromo-mannitol molecule plays a decisive role. Thus the
compound cannot be considered as an analogue of dimesyl-mannitol. In the
competitive tests, the differences between DBM and other alkylating agents
affecting the myeloid line were revealed (Csanyi, 1964). It wastherefore necessary
to perform cross-resistance tests.
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TABLE II.-Cross-resistance Tests on Yoshida s.c. Sarcoma and onDBM Resistant
D-Yoshida s.c. Sarcoma
Yoshida s.C. sarcoma D-Yoshida s.c. sarcoma
Dose Weight of Weight of Change in
mg/kg tumour Inhibition tumour Inhibition body-weight
Agent 5 x i.p. mg. % P* mg. % %
Control . - . 2490 i 280 - . 3440 ± 592 - . +5
DBM . 70 . 25 11 99-1 . 0-01 . 2600 420 24 . +1
Mannitol
Myleran . 70 . 22 10 99.1 . 0-01 . 1570 154 54-3 . +2
Myleran . 10 . 10 5 99-6 . 0-01 . 1350 265 60-8 . -35
Dibromdulcitol . 20 . 10 2 99-6 . 0-01 . 2130 457 41 . +2
Degranol . 10 . 1010 9 99-6 . 0-01 . 1720 281 50 . -5
Mitomycin-C 0-5 . 12 2 99 5 . 0-01 . 1340 309 61 . -13
Fluorouracyl . 20 . 930 ± 423 63-0 . 0-5 . 1550 ± 472 55 . -2t
Control . - . 2180 ± 146 - . 1341 ± 121 . +1
Mitomen 1 . 158 ± 14 90-0 . 0-01 . 1204 ± 124 34 . +3-7
Methotrexate 0-2 . 76 8 97-0 0-51 . 56 8 95-8 . +15
Vinblastine . 0-2 2 262 ± 32 89-0 . 0-5 . 158 ± 15 88-6 6 +4
Control . - 8270 ± 790 - . 2467 ± 320 . +40
Bayer E-39 . 0-2 . 20 ± 3 99-9 . 0-01 . 2150 ± 202 12 . +21
Thio-TEPA 2-0 . 30 ± 5 99-9 . 0-01 . 1480 ± 149 41 . +20
Control . - . 3490 ± 360 - - 2300 ± 142 . +16
Leukeran 1-0 630 ± 3 84-0 . 0-01 . 1794 ± 96 22 . +8
R-74** . 1-0 . 226 ± 32 94-3 . 0-01 . 1790 ± 78 22 . +10
Actinomycin-C . 0-07 . 2190 ± 142 44-5 . 0-5 . 827 ± 58 64 - +4
Tris-mustard . 0-05 . 90 ± 18 98-0 . 0-01 . 2470 ± 328 0 . +11
* - compared to the inhibition on D-Yoshida sarc.
** - 1,4-di/mesyloxyethylamino'-1,4-dideoxy-m-erythritol dichlorhydrate
t = 2/8 death.
The results of these experiments provide clear cut evidence of the alkylating
nature of DBM, though its mechanism of action has not been established with
certainty. The DBM-resistant tumour was found to be resistant both to agents
classified into the lymphoid-active class (Elson, 1958) mustard derivatives,
ethyleneimines and to myeloid-active compounds (Myleran, Mannitol-Myleran),
and was found resistant also to another halogen sugar alcohol, namely to dibro-
modulcitol. Similarly to other resistant substrains, this type of tumour was also
resistant to Mytomycin C.
The failure ofthis tumourtobecomeresistanttoantimetabolitetypecompounds
excludes the possibility of some antimetabolic-like action of the drug which
anyway seemed unlikely by our earlier experiments. Our described results give
further evidence ofthe common-feature ofalkylating agents, as far as its principal
behaviour is concerned, in spite ofits quite different chemical structure. Thus we
can support the conclusions that the differences among individual effective
biological alkylating agents may be in relation with their chemical and physio-
chemical properties and not directly related to their alkylating potency.
SUMMARY
A new DBM-resistant Yoshida s.c. sarcoma strain has been developed by
means ofthe continuous adaptation method.DBM RESISTANT YOSHIDA SARCOMA 357
The degree of resistance of the D-Yoshida s.c. sarcoma was established at the
20th generation. It has been found to be 260-fold.
Several cross-resistance tests have been carried out with various types of
antineoplastic agents. The data ofthese investigations demonstrated the presence
of resistance to a variety of biological alkylating agents and also to Mitomycin.
The D-Yoshida sarcoma strain was, however, sensitive to antimetabolites and
mitotic poisons. These data provide valuable evidence of the alkylating nature
of 1,6-dibromo-1,6-dideoxy-d-mannitol(DBM), MyelobromolR Chinoin.
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